Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma

Leukemia and Lymphoma

Volumn 46, Issue 4, 2005, Pages 567-569

  Schmielau, Jan ^a   Teschendorf, Christian ^b   König, Matthias ^c   Schmiegel, Wolff ^b   Graeven, Ullrich ^b  

^a Sana Kliniken GmbH and Co KGaA   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Bortezomib; Multiple myeloma; Proteasome inhibitor; Thalidomide

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN D; MELPHALAN; PROTEINASE INHIBITOR; THALIDOMIDE; VINCRISTINE;

ADD ON THERAPY; ADULT; ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REMISSION; SALVAGE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FATAL OUTCOME; HUMANS; IMMUNOGLOBULIN D; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE;

EID: 17844372269     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400029700     Document Type: Article

References (7)

1. Paramore A, Frantz S. Bortezomib. Nat Rev 2003;2:611-612.
2. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2002;22:4953-4963.
3. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-4530.
4. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-6325.
5. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98:3846-3848.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
7. Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B, Shaughnessy JD, Anaissie EJ, Thertulien R, Fassas A, et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003;102:236a.